News

Managed Healthcare Executive10h
FDA Sets Action Date for Oral Wegovy for Weight Loss
A decision is expected in the fourth quarter of 2025.
Novo Nordisk says oral version of Wegovy accepted for FDA review
Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.
Howard County man sues Ozempic manufacturer for loss of vision
A Maryland man has filed a lawsuit against the manufacturers of Ozempic, alleging that his use of the drug led to him ...
24/7 Wall St.11d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Wegovy Treats a Serious Form of Liver Disease In a Major Clinical Trial
In a major clinical trial, the weight loss drug Wegovy has been able to treat a serious form of liver disease in the majority ...
Fierce Healthcare3d
Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...
The Victoria Advocate4d
Novo Nordisk expands patient access to authentic, FDA-approved Wegovy® via collaborations with multiple telehealth organizations
PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding ... We believe patients living with this chronic disease who want and need treatment under the ...